Pritumumab

Drug Profile

Pritumumab

Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11

Latest Information Update: 22 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of California, San Diego
  • Developer Nascent Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma

Most Recent Events

  • 19 Jul 2016 Nascent Biotech enters into an exclusive licensing agreement with Zhejiang Hisun Pharmaceutical Company for development, manufacture and commercialisation of pritumumab in China
  • 25 Apr 2016 Pritumumab receives Orphan Drug status for Pancreatic cancer in USA
  • 14 Apr 2016 Pharmacodynamics and pharmacokinetics data from preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top